Alumis Inc (ALMS)

• Market cap: $2.98B
• 1 day: 1.56%
• 5 days: 11.74%
• 1 month: 10.69%
• 3 months: -7.91%
• 6 months: 111.66%
• Year to date: 161.27%
• 1 year: 677.74%
• 5 years: 76.02%
• 10 years: 76.02%
• Sector: Healthcare
• Industry: Biotechnology

About: Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Employees: 227